U.S. Markets closed

Tesaro, Inc. (TSRO)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
113.86+4.81 (+4.41%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close109.05
Bid92.00 x 200
Ask166.00 x 100
Day's Range107.50 - 115.72
52 Week Range83.26 - 192.94
Avg. Volume1,280,546
Market Cap6.13B
PE Ratio (TTM)-13.36
EPS (TTM)-8.52
Earnings DateNov 1, 2017 - Nov 6, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est170.25
Trade prices are not sourced from all markets
  • Barrons.com18 hours ago

    Tesaro: Losing Its Edge?

    The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.

  • Barrons.com20 hours ago

    Ovarian Cancer Market Still Up For Grabs

    The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.

  • ACCESSWIREyesterday

    Featured Company News - Moleculin Biotech Acquires Active Drug Compound for the Treatment of Brain Cancer

    Research Desk Line-up: Tesaro Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Moleculin ...